Patents by Inventor Robert J. Kinders

Robert J. Kinders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277360
    Abstract: A three-dimensional heterogenous cell spheroid comprising a plurality of at least two different types of cells and one or more short peptide cell linkers. The peptide cell linkers are linear peptides having respective terminal ends, and comprising an adhesion sequence at or near each end, with a suitable spacer sequence between each adhesion sequence. Methods of making and using such spheroids for in vitro testing are also described.
    Type: Application
    Filed: July 15, 2019
    Publication date: September 9, 2021
    Inventors: Thu Annelise Nguyen, Ralph E. Parchment, Robert J. Kinders
  • Publication number: 20200354468
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties, products, compositions and kits comprising the monoclonal antibodies, methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 12, 2020
    Publication date: November 12, 2020
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Patent number: 10711068
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Publication number: 20180105598
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Application
    Filed: March 28, 2016
    Publication date: April 19, 2018
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SERECTARY, DEPARTMENT OF H
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Patent number: 9644037
    Abstract: Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: May 9, 2017
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas D. Pfister, Allison M. Marrero, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders
  • Patent number: 6811990
    Abstract: The present invention provides a set of methods and compositions for homogeneous coupled luminescent assays of cytotoxicity and/or proliferation of cells, as well as for enzymatic activity. In both cases the activities of the enzymes of interest are coupled to production of a high-energy molecule, which serves as a substrate for the production of light by a luciferase, typically in a single reagent mixture, with a useful readout available in 1—5 minutes. Individual cytotoxicity and proliferation signals can be measured from a single sample in 6 minutes or less. The invention also provides a 3-minute, one-step phosphatase assay. The ability to couple the activity of interest to light production in a one-step procedure gives rise to extremely rapid and flexible methods for measurement of cytotoxic effects and enzymatic activities. The assay methods are highly suitable for use in high-throughput screening procedures.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: November 2, 2004
    Inventors: Michael J. Corey, Robert J. Kinders
  • Publication number: 20020106765
    Abstract: Methods of screening for and/or detecting the presence or absence of cancers or treating cancers are described. In an aspect of the present invention, the screening methods are based on the detection of the PAL-18 protein, variants thereof, or a nucleic acid molecules encoding the same, found to be associated with the presence of cancer. Additional methods for imaging using antibodies for PAL-18 or modulating PAL-18 are provided. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen (e.g., PAL-18) based on nucleic acid amplification.
    Type: Application
    Filed: March 12, 2001
    Publication date: August 8, 2002
    Inventors: Robert J. Kinders, Michael J. Corey
  • Publication number: 20010023066
    Abstract: Methods of screening for cancers or treating cancers or autoimmune disorders are disclosed. In an aspect of the present invention, the screening methods are based on the detection of complement C3 or C3 related protein, or a nucleic acid molecule encoding the same, found to be associated with the presence of cancer. Additional screening methods are based on the use of complement regulators Factor I or DAF, or complement receptors 1 or 3. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen based on nucleic acid amplification.
    Type: Application
    Filed: March 5, 2001
    Publication date: September 20, 2001
    Inventors: Robert J. Kinders, David L. Enfield, G. Michael Hass
  • Patent number: 6221621
    Abstract: Methods of screening for cancers or treating cancers or autoimmune disorders are disclosed. In an aspect of the present invention, the screening methods are based on the detection of complement C3 or C3 related protein, or a nucleic acid molecule encoding the same, found to be associated with the presence of cancer. Additional screening methods are based on the use of complement regulators Factor I or DAF, or complement receptors 1 or 3. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen based on nucleic acid amplification.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: April 24, 2001
    Assignee: BARD Diagnostic Sciences, Inc.
    Inventors: Robert J. Kinders, David L. Enfield, G. Michael Hass
  • Patent number: 6017703
    Abstract: Methods of screening for or treating cancer are disclosed. The screening methods are based on the detection of an antigen, or a nucleic acid molecule encoding the antigen, found by the present invention to be associated with the presence of cancer. Preferred embodiments of the methods include detection of the antigen based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding the antigen based on nucleic acid amplification.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: January 25, 2000
    Assignee: Bard Diagnostic Sciences, Inc.
    Inventors: Robert J. Kinders, David L. Enfield, G. Michael Hass